FindTrial
Sign In

Validation study of FEC followed by docetaxel as preoperative chemotherapy in primary beast cancer (JBCRG-02')

Validation study of FEC followed by docetaxel as preoperative chemotherapy in primary beast cancer (JBCRG-02') - Validation study of FEC followed by docetaxel as preoperative chemotherapy in primary beast cancer (JBCRG-02')

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000320
Enrollment
20
Registered
2006-02-02
Start date
2005-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary breast cancer

Interventions

Primary systemic chemotherapy: fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2, q3w x 4 cycles + Docetaxel 100 mg/m2, q3w x 4 cycles

Sponsors

Japan Breast Cancer Reaserch Group (JBCRG)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Histologiccally-proven breast cancer T1c-3N0M0/T1-3N1M0 No prior therapy for breast cancer Performance status 0-1 Adequate hematologic, renal, hepatic and cardiac function Written informed consent

Exclusion criteria

Exclusion criteria: Hypersensitivity for drugs Serious coexisting illness Active double cancer Bilateral breast cancer Male breast cancer Pregnant or postpartum wemen

Design outcomes

Primary

MeasureTime frame
Safety, clinical and pathological response—

Secondary

MeasureTime frame
Breast-conserving rate, disease-free survival—

Countries

Japan

Contacts

Public ContactKatsumasa Kuroi

JBCRG Head office

office@jbcrg.jp03-6264-8873

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026